Reviewer's report

*Title:* Progressive Cholinergic Decline in Alzheimer’s Disease: Consideration for Treatment With Donepezil 23 mg in Patients With Moderate to Severe Symptomatology

*Version:* 1 *Date:* 18 December 2010

*Reviewer:* Rajesh Tampi

**Reviewer's report:**

Minor Essential Revision

It must be mentioned that the Farlow et al study which forms the basis for their recommendation was a study lasting only 24 weeks (6 months), a short time for the treatment of patients with dementia. Without mentioning this fact it will appear that the higher dose of donepezil (23 mg a day) can provide sustained cognitive (SIB) or global benefit (CIBIC-PLUS) in patients with moderate to severe dementia.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** Yes, and I have assessed the statistics in my report.

**Declaration of competing interests:**

I declare that I have no competing interests